Results 171 to 180 of about 4,891,805 (263)

Understanding the cellular architecture of Huntington's disease. [PDF]

Elife
Pustina D.
europepmc   +1 more source

GLP‐1R agonist semaglutide protects human forebrain organoids from cholesterol‐induced neurotoxicity

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Dysregulated cholesterol metabolism represents a critical metabolic stressor in the central nervous system, contributing to neuronal injury across multiple neurological conditions, including Alzheimer's disease (AD). While glucagon‐like peptide‐1 receptor (GLP‐1R) agonists show neuroprotective potential, their capacity to directly
Feifei Yu, Jiani Xu, Yibo Hou, Honghui Zheng, Lingyi Guo, Davit Khutsishvili, Cheng Hai, Wenxin Xu, Bailing Chen, Zitian Wang, Shaohua Ma   +10 more
wiley   +1 more source

Regional and Compartmental Changes Drive Progressive Patterns of Striatal Degeneration in X‐Linked Dystonia Parkinsonism

Annals of Neurology, Volume 100, Issue 4, Page 751-767, October 2026.
Objective Initially described in 1976, X‐linked dystonia parkinsonism (XDP) is a neurodegenerative disease that can be characterized by the presentation of dystonia and parkinsonism symptoms. Although this disease bears some resemblance to other neurodegenerative diseases in terms of symptomatology, the pathological signature of XDP is still unclear ...
Adelie Y.S. Tan, Nakhon. S.S.S. Thai, Christine J. Arasaratnam, Seung A. Han, Ellen B. Penney, Geraldine Acuña‐Sunshine, Cid Czarina E. Diesta, Mark C. Ang, Edwin Muñoz, Cara Fernandez‐Cerado, Victor Cleofas, G. Paul Legarda, Salvie Velasco, Michelle A. Sy, Clinton P. Turner, Mike Dragunow, Maurice A. Curtis, Ann. M. Graybiel, Richard L.M. Faull, Malvindar K. Singh‐Bains   +19 more
wiley   +1 more source

A new hope for patients with Huntington's disease? [PDF]

EClinicalMedicine
eClinicalMedicine.
europepmc   +1 more source

Glymphatic System Dysfunction and its Associated Factors in Wilson's Disease: A DTI–ALPS Study

Brain and Behavior, Volume 16, Issue 10, October 2026.
Glymphatic function, assessed by DTI‐ALPS index, was impaired in neurological Wilson's disease compared with hepatic phenotype and controls. Age, AST, and UWDRS‐I score independently predicted dysfunction, linking neurodegeneration, liver injury, and altered glymphatic activity. ABSTRACT Background Wilson's disease (WD) is a genetic disorder of copper (
Ling Zhu, Tong Wu, Liang‐Jie Zhang, Qin‐yuan Liu, Liang‐liang Zhang, Bin Song, Yu‐long Zhu, Lei Hua, Long Zhang, Bo Li, Quan Sun, Ben‐chun Xue, Yin Xu, Yong‐zhu Han, Yong‐sheng Han   +14 more
wiley   +1 more source

Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025. [PDF]

Mov Disord
Konstantinova P, Townhill J, Bronzova J, Andreeva V, Sathe S, Sampaio C.   +5 more
europepmc   +1 more source

On the importance of including both sexes in animal studies – insights from home‐cage monitoring

Biological Reviews, Volume 101, Issue 5, Page 2408-2426, October 2026.
ABSTRACT A review of behavioural studies using home‐cage monitoring (HCM) systems revealed that over 61% of studies used only male subjects, with only 24% including both sexes, despite evidence of substantial behavioural differences between male and female animals. This bias could influence the outcomes of biomedical research.
Maša Čater, Adam Dušek, Aleksandra Bartelik, Silvia Mandillo, Elisabetta Golini, Mara Rigamonti, Rasneer Sonia Bains, Hamish Forrest, Marion Rivalan, Melissa Long, Anna Kiryk, Lars Lewejohann, Nuno Henrique Franco   +12 more
wiley   +1 more source

Factors Associated With Perceived Cognitive Dysfunction in Patients With Primary Brain Tumors: The Utility of the Neuro‐QoL Cognition Function Scale

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Primary brain tumor (PBT) patients commonly experience cognitive dysfunction. This study aims to describe the prevalence and factors associated with perceived cognitive function (PCF) in PBT patients enrolled in a natural history study (NCT02851706: Principal Investigator T. S. Armstrong).
Morgan Johnson, Kimberly Reinhart, Vivian A. Guedes, Michelle L. Wright, Elizabeth Vera, Alvina Acquaye‐Mallory, Hope Miller, Anna Choi, Tricia Kunst, Jennifer Reyes, Jing Wu, Marta Penas‐Prado, Byram Ozer, Eric Burton, Mark R. Gilbert, Terri S. Armstrong, Tito Mendoza   +16 more
wiley   +1 more source

Factors influencing receipt of specialty neurologic care for patients with Huntington's disease in Colorado. [PDF]

Clin Park Relat Disord
Ogilvie AC, Forbes E, Lin CC, Burke JF, Lum HD, Reed SM.   +5 more
europepmc   +1 more source

CRISPR‐based therapeutic and modelling approaches in Huntington's disease: Progress, challenges and future directions

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Clustered regularly interspaced short palindromic repeat (CRISPR) is transforming Huntington's disease research through allele‐selective huntingtin (HTT) targeting, transcriptional and RNA suppression, and advanced disease modelling. Progress towards precision therapy depends on safe central nervous system (CNS) delivery, reduced off‐target and immune ...
Kairat Zhakipbekov, Surayyo Eshkabilova, Zokir Raximov, Sharof Eshonov, Abdusaid Khasanov, Ziyodulla Tokhtamurod, Axmadjan Ashurmetov, Avazbek Abduraxmanov, Niyozbek Abdurakhmonov, Elmurod Eshqobilov, Seyed Mohsen Mirhosseini, Amir Arsalan Ghahari   +11 more
wiley   +1 more source